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men. In patients aged 80 years, 3 months of anticoagulation was more
effective and less costly than other strategies. The risk associated with recurrent
VTE, the disutility of taking warfarin, and major bleeding risk of conventional-
intensity anticoagulation all influenced cost-effectiveness results.
Comment: Treatment of VTE is becoming more individualized. The
strategies outlined in the paper make sense in that they incorporate recent
findings concerning the natural history and the treatment of idiopathic VTE.
By taking into account sex, age, risk of bleeding, and the cost and difficulties
of warfarin therapy, the authors have proposed a reasonable outline for
treatment of idiopathic VTE in both men and women.
Endovascular repair or surveillance of patients with small AAA
Zarins CK, Crabtree T, Arko FR, et al. Eur J Vasc Endovasc Surg 2005;29:
496-503.
Conclusion: In patients with small (4.5 to 5.5 cm) abdominal aortic
aneurysms (AAA), endovascular repair when compared with ultrasound
surveillance and selective open surgery may result in a decreased risk of fatal
aneurysm rupture and aneurysm-related death, with improved patient sur-
vival.
Summary: This was a statistical analysis comparing patients random-
ized to the surveillance arm of the UK Small Aneurysm trial with patients in
a prospective trial of endovascular AAA repair. Endovascular repair patients
were selected from the AneuRx clinical trial cohort that was treated with a
stent-graft from 1997 to 1999 (EVAR Small), with follow-up through
2003. A subgroup of these patients (EVAR Match) who met age and
aneurysm size requirements for inclusion in the UK Small Aneurysm trial
were then compared with the results of the surveillance group (UK Surveil)
with respect to aneurysm rupture, fatal aneurysm rupture, operative mortal-
ity, aneurysm death, and overall mortality. To account for differing lengths
of follow-up end points between the EVARMatch and UK Surveil, patients
were compared using rates per 100 patient years of follow-up.
There were 312 patients in the EVARMatch group. One hundred and
fifty-one patients in the EVAR Small group were excluded for inclusion in
the EVARMatch group because of age60 or76 years or AAA diameter
4 cm. With the exception of age, there were no differences between the
EVAR Small and EVAR Match groups. In comparison with the UK Surveil
group of 527 patients, patients in the EVARMatch group were older (70
4 years vs 69 4 years, P .009) and had larger aneurysms (5.0 0.3 cm.
vs 4.6  0.4 cm, P  .001). There were also fewer women in the EVAR
Match group (7% vs 18%, P  .001). The EVAR Match group also had a
higher prevalence of diabetes mellitus and hypertension and a lower inci-
dence of cigarette smoking than the UK Surveil group.
After adjusting for follow-up time, fatal aneurysm rupture was four
times higher in the UK Surveil group (0.8/100 patient years) than in the
EVAR Match group (0.2/100 patient years). Selected operative morbidity
in the EVARMatch groupwas 1.9%, whereas theUK Surveil groupwas 5.9%
(P .01). Overall ruptures occurred in 1.6% of EVARMatch patients and in
5.1% of UK Surveil patients. This difference was not statistically significant.
Elective operative mortality was significantly higher in the UK Surveil vs
EVAR Match group (5.9% vs 1.9%, P  .01). All-cause mortality was signifi-
cantly higher in theUKSurveil group than in theEVARMatchgroup (8.3/100
patient years vs 6.4/100 patient years, P  .02). Aneurysm-related death was
two times higher in the UK Surveil group (1.6/100 patient years) than in the
EVARMatch group (0.8 vs 100 patient years, P .03).
Comment: This article was accompanied by invited commentaries in
the European Journal of Vascular and Endovascular Surgery. Commentaries
indicate two polarized views of the “interesting” manipulation of statistics
presented in the paper. Dr Brunkwall argued that the “article strongly
supports the need for trials of EVAR vs Surveillance in small aneurysms.” Dr
Powell stated “there is just a suspicion that Zarins and colleagues are using
inappropriate comparisons in an attempt to find new markets for endovas-
cular devices.” As in most cases of widely disparate opinions, there is
probably some truth to both points of view.
Embolic protection devices for carotid artery stenting: Is there a
difference between filter and distal occlusive devices?
Zahn R, Ischinger T, Mark B, et al. J Am Coll Cardiol 2005;45:1769-74.
Conclusion: Filter type embolic protection devices are the currently
preferred method of embolic protection in clinical practice of carotid artery
stenting.
Summary: The authors sought to evaluate filter embolic protection
devices (F-EPD) and distal occlusive protection devices (DO-EPD) in
carotid artery stenting (CAS). Data from July 1996 to July 2003 were
analyzed from the carotid artery stent registry, an ongoing registry of carotid
artery stenting established in 1996 (Eur Heart J 2004;25:1558-8). During
this period, 1,734 patients were entered into the CAS registry. Of these, 176
(24.1%) were treated with DO-EPDs, and 729 patients were treated with an
F-EPD protection device (N  553, 75.9%). Carotid lesions treated in
patients with DO-EPDs had a higher proportion of ulcers, severe calcifica-
tion, longer lesion lengths, and a higher preintervention grade of stenosis (P
 .001). Treatment durations were a mean of 30 minutes in the DO-EPDs
and a mean of 48 minutes in the F-EPDs (P  .001). There was no
difference in clinical events between the two groups of protection devices
examined. There was no difference in the combined end point of in-hospital
death or stroke between filter andDO-EPDs (adjusted odds ratio, 1.04; 95%
CI, 0.24 to 4.44; P  0.958).
Comment: The data indicate that filter embolic protection devices are
preferred over occlusive embolic protection devices indicated by the larger
percentage of patients were treated with filter embolic protection devices in
this registry. Nevertheless, filter and occlusive protection embolic protection
device appear to have about the same efficacy during CAS. Obviously, likely
what matters is keeping particulate matter out of the brain during CAS. At
this point, it appears embolic protection devices can be chosen based on
relative ease of use and individual operator preference.
MMP-12 has a role in abdominal aortic aneurysms in mice
Longo GM, Buda SJ, Fiotta N, et al. Surgery 2005;137:457-62.
Conclusion: Matrix metalloproteinase-12 (MMP-12) deficiency at-
tenuates aneurysm growth.
Summary: Degradation of elastin and collagen is important in the initia-
tion and expansion of abdominal aortic aneurysms (AAAs). This degradation of
aortic structural proteins is a result, at least in part, of activity by a family of
endopeptidases termed matrix metalloproteinases (MMPs). The authors uti-
lized a murine aneurysm model in this study. Aortic diameters were measured
and compared before and after 10 weeks of induction of AAAs in the model.
Aneurysm induction was achieved by periaortic application of calcium chloride
for 15 minutes. Aortic diameters were then determined for wild-type mice and
MMP-12 knockoutmice. Production ofMMP-12,MMP-2, andMMP-9were
analyzed by zymographic techniques. Macrophage infiltration into the aorta
was also determined with immunohistochemical techniques.
Wild-type mice, after calcium chloride application to the aorta, had
an increase in the aortic diameter of 63%  5%, whereas MMP-12
knockout mice had an increase in aortic diameter of only 26% 14% after
calcium chloride induction. Aortic sections from wild-type mice showed
fragmentation and disruption of medial elastic fibers, whereas aortic
sections from MMP-12 knockout mice showed only focal areas of elastic
lamellae breakdown. There was a significant increase in MMP-12 levels in
wild-type mice after calcium chloride exposure. There was no increase in
MMP-12 levels in MMP-12 knockout mice after calcium chloride expo-
sure. MMP-9 and MMP-2 levels did not change in the wild type and
MMP-12 knockout mice. There were fewer infiltrating macrophages in
the aorta of the MMP-12 knockout mice than in wild-type controls.
Comment: This study supports the hypothesis that MNP-12 plays
some role in AAA pathogenesis. The major source of MMP-12 in vivo is the
macrophage. The macrophage may thus play an important role in aneurysm
formation. Macrophages can convert pro-MMP-12 to an active form and
trigger lysis of the elastic component of the aortic wall, resulting in medial
destruction and aneurysm formation.
Effect of C-reactive protein on gene expression in vascular endothe-
lial cells
Wang Q, Zhu X, Xu Q, et al. Am J Physiol Heart Circ Physiol 2005;288:
H1539-45.
Conclusion:C-reactive protein (CRP), in a dose-dependent fashion, is
associated with specific up- and downregulation of genes that may be
involved in vascular endothelial cell function.
Summary: It is known increased levels of CRP are associated with risk
for coronary artery disease and may have associated risk for arterial disease
elsewhere as well. The authors studied the effects of CRP on gene expression
of vascular endothelial cells. They used microarray analysis along with
polymerase chain reactions to measure gene expression from human vascular
endothelial cells (human aortic endothelial cells and human umbilical vein
endothelial cells). The cells were incubated with CRP at concentrations
varying from 0 to 10 g/mL.
Genetic microarray analysis demonstrated 11 genes had increased
expression, and six genes had decreased expression as defined by a greater
than twofold change in their messenger RNA levels. Interleukin (IL)-8 was
the most significantly upregulated gene (13.6 times baseline) and had a clear
time- and dose-dependent pattern established by quantitative real-time
polymerase chain reaction. CRP enhanced monocyte adhesion to the endo-
thelial cell monolayer by two times (P  .01). This effect was partially
blocked by anti-IL-8 antibody (34.2% inhibition, P  .01). CRP-induced
IL-8 upregulation could be blocked using U0126, an inhibiter of the
extracellular signal-regulated kinase (ERK)mitogen-activated protein kinase
(MAPK) pathway.
Comment:We are all aware of CRP as a marker of cardiovascular risk.
It is, however, unclear whether CRP itself induces changes detrimental to
the vascular system or is merely a byproduct of other biochemical abnormal-
ities that eventually result in increased atherosclerotic risk. These data
suggest that there are genes that are responsive to CRP levels. Many of the
genes in this study shown to be responsive to CRP have broad functional
roles in cell differentiation, cell growth, and vascular remodeling. These data
do not rule out CRP as primarily a byproduct of some other process. They
do, however, indicate CRP itself possesses biologic activity, through modi-
fication of gene expression, that may affect vascular wall biology and, by
inference, atherosclerosis.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 5 Abstracts 1037
